Detailed characterization of combination treatment with MET inhibitor plus EGFR inhibitor in <i>EGFR</i>-mutant and <i>MET</i>-amplified non-small cell lung cancer.

Transl Lung Cancer Res · 2024 · PMC11535821 · PMID 39507027

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Among these regimens, the regimens that included paclitaxel and platinum, such as ABCP, showed a trend of higher response rates compared to other regimens.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.